PDS Biotechnology Corporation (NASDAQ:PDSB) Sees Significant Increase in Short Interest

PDS Biotechnology Corporation (NASDAQ:PDSB) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,406,521 shares, an increase of 172.7% from the August 31st total of 2,349,694 shares. Approximately 12.5% of the shares of the stock are short sold. Based on an average daily volume of 97,840,279 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of PDS Biotechnology

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in PDS Biotechnology in the 2nd quarter worth approximately $535,000. Bank of New York Mellon Corp bought a new position in PDS Biotechnology in the 2nd quarter valued at $60,000. Finally, Renaissance Technologies LLC increased its stake in shares of PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after buying an additional 44,100 shares during the period. Institutional investors own 26.84% of the company’s stock.

Analyst Ratings Changes

PDSB has been the topic of several analyst reports. Wall Street Zen lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings cut PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, PDS Biotechnology has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

Shares of NASDAQ PDSB traded down $0.03 during mid-day trading on Monday, hitting $0.77. 3,807,508 shares of the stock were exchanged, compared to its average volume of 7,943,553. The company has a market cap of $42.87 million, a P/E ratio of -1.20 and a beta of 1.46. The stock’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.79. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57. PDS Biotechnology has a twelve month low of $0.20 and a twelve month high of $1.55.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). As a group, analysts forecast that PDS Biotechnology will post -0.47 EPS for the current fiscal year.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.